Intensive glycemic control and the risk of end-stage renal disease: an ADVANCE in the management of diabetes?
Posttrial follow-up of participants randomized to intensive versus standard glycemic control in the ADVANCE trial has demonstrated a significant benefit of intensive glycemic control on the risk of end-stage renal disease. In a more detailed analysis, intensive glycemic control appears to be of benefit only before the development of clinically evident kidney disease or in patients with documented early-stage chronic kidney disease.
Department of Medicine, Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: christina.wyatt@mssm.edu.
Christina M
CM
Wyatt
Toronto General Research Institute, University Health Network, Toronto General Hospital, Toronto, Ontario, Canada.
Daniel C
DC
Cattran
D001786:Blood Glucose / Q000032:analysis*; D003920:Diabetes Mellitus; D006801:Humans; D007676:Kidney Failure, Chronic; D051436:Renal Insufficiency, Chronic; D012306:Risk
D001786:Blood Glucose